Analysts Set Geron Co. (NASDAQ:GERN) Price Target at $7.25

Shares of Geron Co. (NASDAQ:GERN - Get Free Report) have been given a consensus recommendation of "Buy" by the twelve ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $6.91.

A number of research analysts have commented on GERN shares. Needham & Company LLC increased their target price on Geron from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Monday, January 13th. HC Wainwright reiterated a "buy" rating and set a $9.00 price target on shares of Geron in a research report on Tuesday, December 10th. Barclays raised Geron to a "strong-buy" rating in a research note on Friday, November 29th. Finally, B. Riley decreased their target price on Geron from $5.50 to $3.50 and set a "buy" rating for the company in a research report on Tuesday.

Hedge Funds Weigh In On Geron

A number of institutional investors have recently made changes to their positions in GERN. SBI Securities Co. Ltd. bought a new position in shares of Geron in the fourth quarter worth about $28,000. Integrated Wealth Concepts LLC bought a new position in shares of Geron in the fourth quarter worth about $36,000. GF Fund Management CO. LTD. acquired a new stake in Geron during the fourth quarter worth about $45,000. Fifth Lane Capital LP acquired a new stake in Geron during the fourth quarter worth about $53,000. Finally, Readystate Asset Management LP acquired a new stake in Geron during the third quarter worth about $58,000. 73.71% of the stock is currently owned by institutional investors.

Geron Price Performance

GERN traded down $0.06 during trading on Friday, reaching $2.58. 8,950,085 shares of the stock were exchanged, compared to its average volume of 11,789,030. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. Geron has a 1 year low of $1.64 and a 1 year high of $5.34. The business's 50 day moving average price is $3.13 and its two-hundred day moving average price is $3.88. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of -8.05 and a beta of 0.53.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.